Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Optimizerx Corp (OPRX)

Optimizerx Corp (OPRX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
8.66 +0.28 (+3.34%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 8.66 unch (unch) 16:01 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.14
Day High
8.86
Open 8.27
Previous Close 8.38 8.38
Volume 144,200 144,200
Avg Vol 231,485 231,485
Stochastic %K 79.46% 79.46%
Weighted Alpha -20.61 -20.61
5-Day Change +0.21 (+2.49%) +0.21 (+2.49%)
52-Week Range 3.78 - 14.13 3.78 - 14.13
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,946
  • Shares Outstanding, K 18,490
  • Annual Sales, $ 92,130 K
  • Annual Income, $ -18,660 K
  • EBIT $ -2 M
  • EBITDA $ 3 M
  • 60-Month Beta 1.18
  • Price/Sales 1.69
  • Price/Cash Flow N/A
  • Price/Book 1.32

Options Overview Details

View History
  • Implied Volatility 89.86% ( -5.49%)
  • Historical Volatility 69.57%
  • IV Percentile 67%
  • IV Rank 54.97%
  • IV High 142.88% on 10/23/24
  • IV Low 25.13% on 09/18/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 57
  • Volume Avg (30-Day) 224
  • Put/Call OI Ratio 1.30
  • Today's Open Interest 7,301
  • Open Int (30-Day) 6,657

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.34
  • Prior Year -0.27
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.80 +27.35%
on 04/08/25
Period Open: 9.47
9.41 -7.97%
on 03/26/25
-0.81 (-8.55%)
since 03/25/25
3-Month
3.99 +116.97%
on 03/11/25
Period Open: 5.43
9.84 -11.99%
on 03/25/25
+3.23 (+59.48%)
since 01/24/25
52-Week
3.78 +129.10%
on 11/15/24
Period Open: 8.80
14.13 -38.71%
on 05/15/24
-0.14 (-1.59%)
since 04/25/24

Most Recent Stories

More News
OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET

OPRX : 8.66 (+3.34%)
OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment

OPRX : 8.66 (+3.34%)
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results

OPRX : 8.66 (+3.34%)
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations

OPRX : 8.66 (+3.34%)
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer

OPRX : 8.66 (+3.34%)
OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET

OPRX : 8.66 (+3.34%)
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO

OPRX : 8.66 (+3.34%)
OptimizeRx to Participate in Upcoming Investor Conferences

OPRX : 8.66 (+3.34%)
OptimizeRx Reports Third Quarter 2024 Financial Results

OPRX : 8.66 (+3.34%)
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET

OPRX : 8.66 (+3.34%)
OptimizeRx Corporation (OPRX) Q2 2022 Earnings Call Transcript

OPRX earnings call for the period ending June 30, 2022.

OPRX : 8.66 (+3.34%)
UPDATE – OptimizeRx Reports Second Quarter 2022 Financial Results, Innovative Platform Expansions Now Extends Reach to HCPs Across Social Media and Patients at Point-of-Dispense

Revenue Up 3% to $14.0 million, driven by new customer and program launchesIncrease in breadth and scope of brand deal size represents further momentum in...

OPRX : 8.66 (+3.34%)
OptimizeRx Reports Second Quarter 2022 Financial Results, Innovative Platform Expansions Now Extends Reach to HCPs Across Social Media and Patients at Point-of-Dispense

Revenue Up 3% to $14.0 million, driven by new customer and program launchesIncrease in breadth and scope of brand deal size represents further momentum in...

OPRX : 8.66 (+3.34%)
OptimizeRx Sets Second Quarter Fiscal 2022 Conference Call for Tuesday, August 9 at 4:30 p.m. ET

ROCHESTER, Mich., July 21, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology...

OPRX : 8.66 (+3.34%)
OptimizeRx Brings Real-World Evidence-Driven Engagement Programs to Social Media With New Exclusive Partnership

The latest omni-channel platform extension gives pharma access to up to 84% of prioritized HCPs on social media with content that is specific to their...

OPRX : 8.66 (+3.34%)
OptimizeRx’s Mike Rousselle Named One of 2022 PM360 ELITE 100

ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology...

OPRX : 8.66 (+3.34%)
OptimizeRx Authorizes $20 Million Share Repurchase Program

ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology...

OPRX : 8.66 (+3.34%)
OptimizeRx to Participate in Upcoming May Conferences

ROCHESTER, Mich., May 10, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology...

OPRX : 8.66 (+3.34%)
3 Small-Caps That Might Be Acquisition Candidates

Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.

OPRX : 8.66 (+3.34%)
AFMD : 0.9347 (+5.02%)
TDOC : 7.20 (-0.83%)
BPMC : 87.66 (+1.82%)
DOCS : 56.65 (+0.64%)
OptimizeRx Reports First Quarter 2022 Financial Results, Revenue Up 22%, Successfully Completes EvinceMed Acquisition

Revenue Up 22% to $13.7 million on increased average revenue per top 20 pharmaceutical manufacturer clientTraction with top 20 pharmaceutical manufacturers...

OPRX : 8.66 (+3.34%)

Business Summary

OptimizeRx Corporation provides consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products. It offers pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. The Company offers...

See More

Key Turning Points

3rd Resistance Point 9.69
2nd Resistance Point 9.27
1st Resistance Point 8.97
Last Price 8.66
1st Support Level 8.25
2nd Support Level 7.83
3rd Support Level 7.53

See More

52-Week High 14.13
Fibonacci 61.8% 10.18
Fibonacci 50% 8.95
Last Price 8.66
Fibonacci 38.2% 7.73
52-Week Low 3.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective